Community
Explore discussions and connect with other members of the Peptide Pen Community.
Visit the community →
Triple-receptor research, explained before checkout.
Reta One-Click Retatrutide is an investigational GIP, GLP-1 and glucagon receptor agonist. This listing is for research purposes only and is not an approved weight-loss treatment.
Research use only. Not for human consumption. Reta One-Click is investigational and is not an approved weight-loss treatment.
The active compound in Reta One-Click is being evaluated as a once-weekly triple-receptor agonist in clinical trials. Published trial records describe activity at the GIP, GLP-1 and glucagon receptors. Positive Phase 3 results do not mean the medicine is approved: regulatory review is a separate process.
Join the discussion, ask a question or continue to checkout when you are ready.
Explore discussions and connect with other members of the Peptide Pen Community.
Visit the community →Have a question? Start a consultation before deciding on your next step.
Start a consultation →Review your order, enter your details and follow the cryptocurrency payment instructions.
Continue to checkout →No. Reta One-Click remains investigational. This product listing is presented for research purposes only and not as an approved treatment.
The catalogue configuration is listed as four 10mg units. Confirm the selected item and final order details on the checkout screen before paying.
The BuyOnlineMedication.com checkout passes this product to the existing licensed crypto payment flow. The final price and available payment options are shown there.
Use the primary-source links on this page for the current ClinicalTrials.gov record and the sponsor's Phase 3 programme update.
Review the final item, declarations, payment options and total in the existing crypto checkout before paying.